Providers/Grant Support
Provided by EXCEL Continuing Education.
This activity is supported by an independent education grant from CELLTRION USA.
Credits Available
- Physicians — maximum of 1 AMA PRA Category 1 Credit™
- Nurses — 1 Nursing Contact Hour
All other healthcare professionals completing this course will be given a statement of participation (non-physicians).
Target Audience
This activity is designed to meet the educational needs of pediatric dermatologists, general dermatologists, pediatricians, primary care providers, and allied healthcare providers to improve their awareness, diagnosis, and management of children with psoriasis using biosimilars as an alternative treatment option.
Program Overview
This activity will explore advancements in the understanding and application of biosimilars for the management of inflammatory diseases, with a particular focus on their role in psoriasis treatment.
Biosimilars are complex biologic agents derived from living organisms that demonstrate high similarity to an FDA-approved reference product in terms of structure, function, and clinical performance, with no clinically meaningful differences in safety, purity, or potency. While biosimilars are well-established in Europe, adoption of these agents in the United States has been slower but accelerating due to increased FDA approvals and payer-driven substitution. Clinicians face challenges in staying current with the rapidly changing landscape of psoriatic therapeutic options. This educational initiative will examine the evidence supporting the safety, efficacy, and clinical integration of biosimilars, offering an alternative to conventional biologics and expanding patient access to high-quality biologic treatments.
Learning Objectives
Upon completion of this activity, participants should be better able to:
- Define biosimilars and how these new agents can help close the treatment gap for managing children with psoriatic diseases
- Accurately identify clinical presentations of pediatric psoriatic disease to facilitate an earlier diagnosis and treatment initiation while differentiating it from mimicking conditions
- Discuss new and emerging treatment options for pediatric psoriasis
- Review pediatric patient cases using real-world scenarios
Faculty
Mercedes E. Gonzalez, MD
Clinical Assistant Professor of Dermatology
Florida International University Herbert Wertheim College of Medicine
Phillip Frost Department of Dermatology
University of Miami Miller School of Medicine
Miami, FL
Amanda T. Moon, MD, FAAD
Attending Physician
Dermatology Section
Children’s Hospital of Philadelphia
Philadelphia, PA
Accreditation Statement
EXCEL Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Credit Designation
EXCEL Continuing Education designates this enduring activity for a maximum of 1.0 AMA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
NURSES: EXCEL Continuing Education is accredited by the Florida Board of Nursing, Provider # 50-619 and designates this activity for 1 nursing contact hour.
Disclosures of Conflicts of Interest
Amanda T. Moon, MD
- Relationship: DynaMed. Medical Editor/Writer.
Mercedes E. Gonzalez, MD
- Principal Investigator: AbbVie, Arcutis, Dermavant, Eli Lilly, Krystal Biotech, Pfizer, Regeneron, Sanofi Genzyme, Verrica Pharma, Sun Pharma Neilsen Biosciences.
- Speaker: AbbVie, Organon, ely Lilly, Krystal Biotech, Sanofi, Regeneron, Verrica, Pelthos, Pfizer.
- Consultant: Abeona, Alphyn, Amyrt, Arcutis, Cerave, Drmavant, Eli Lilly, Incyte, Galderma, Organon, Regeneron, Sanofi, Verrica, Pelthos.
Instructions for Participation and Credit
There are no fees for participating and receiving CME credit for this enduring activity. To receive CME credit participants must:
- Read the CME/CE information and faculty disclosures.
- Participate in the online activity.
- Submit the evaluation form.
Certificates will be immediately available for the participant.
Disclosure of Unlabeled Use
EXCEL Continuing Education requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
Disclaimer
This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
Contact Information
For CME questions please contact: [email protected].